Navigating the international procurement of recombinant proteins requires strict compliance with analytical purity standards and verifiable manufacturing protocols. For laboratory investigators searching to source high-purity follistatine peptide online (follistatine peptide online kopen), PX1 Research provides verified, US-manufactured peptides complete with lot-specific analytical documentation for advanced in vitro and preclinical research.
Navigating the international procurement of recombinant proteins requires strict compliance with analytical purity standards and verifiable manufacturing protocols. For laboratory investigators searching to source high-purity follistatine peptide online (follistatine peptide online kopen), PX1 Research provides verified, US-manufactured peptides complete with lot-specific analytical documentation for advanced in vitro and preclinical research.
For researchers seeking to procure research-grade follistatin online (follistatine peptide online kopen), high-purity recombinant Follistatin must be sourced exclusively from accredited US manufacturers providing lot-specific certificates of analysis (COA). PX1 Research supplies laboratory-grade Follistatin-315 research peptide (>98% purity verified via RP-HPLC and LC-MS) exclusively for in vitro and animal research applications.
When issuing institutional purchase orders or procuring reference standards across European and international jurisdictions, verifying analytical transparency is paramount. Substandard or unverified peptide batches can introduce confounding variables into cell culture assays and animal models due to sequence truncations, residual heavy metals, or endotoxin contamination. PX1 Research eliminates research variability by ensuring every batch undergoes rigorous analytical testing in ISO 17025 accredited laboratories prior to distribution.
Follistatin (FST) is an autocrine, monomeric glycoprotein expressed in virtually all mammalian tissues. Encoded by a single gene, alternative mRNA splicing and post-translational modification give rise to distinct isoforms that vary significantly in length, tissue localization, and heparin-binding affinity. The primary isoforms evaluated in growth factor signaling compounds models include FST-288, FST-315, and the precursor protein FST-344.
FST-288 represents the membrane-bound isoform, characterized by a potent basic C-terminal domain with high affinity for cell-surface heparan sulfate proteoglycans. This heparin-binding capability restricts FST-288 largely to local tissue compartments. In contrast, FST-315 is the predominant circulating isoform found in systemic plasma. The additional 27 amino acid C-terminal tail in FST-315 neutralizes its basic charge, shielding the heparin-binding domain and allowing the protein to circulate freely until carboxyl-terminal cleavage occurs.
Understanding these structural differences is essential for designing valid preclinical research protocols. Investigators selecting a Follistatin peptide variant must match the specific isoform's pharmacokinetic profile to their analytical objective, whether targeting systemic endocrine cascades or localized autocrine tissue responses.
The primary mechanism of action of Follistatin involves the high-affinity binding and stoichiometric neutralization of regulatory proteins within the Transforming Growth Factor-beta (TGF-β) superfamily. Specifically, Follistatin functions as a potent antagonist to activin A, activin B, and myostatin (Growth Differentiation Factor 8 / GDF-8). By binding to these ligands, Follistatin prevents them from interacting with their respective transmembrane receptors, primarily Activin Type II Receptors (ActRIIA and ActRIIB).
In physiological signaling, myostatin binds to ActRIIB, initiating a phosphorylation cascade involving Smad2 and Smad3 transcription factors. This intracellular pathway downregulates protein synthesis via the Akt/mTOR network and upregulates ubiquitin-proteasome system components such as MuRF-1 and Atrogin-1, promoting muscle protein degradation. When Follistatin sequesters myostatin in a 1:2 stoichiometry, it blocks this inhibitory cascade, maintaining baseline protein synthesis pathways.
Preclinical data indicate that Follistatin's affinity for activin is significantly higher than its affinity for myostatin. However, because activin and myostatin share signaling cross-talk through ActRIIB receptors, dual neutralization by Follistatin results in a profound shift in intracellular signaling, making it a critical focus area within myostatin inhibitors research.
The scientific literature regarding Follistatin spans rodent mutagenesis models, tissue regeneration studies, and fibrosis suppression assays. Early transgenic mouse models overexpressing Follistatin demonstrated dramatic skeletal muscle hypertrophy, exhibiting muscle mass increases of 100% to 200% compared to wild-type controls. Subsequent comparative studies revealed that this hypertrophic phenotype exceeded that seen in myostatin-knockout mice alone, suggesting that Follistatin operates through additional pathways independent of myostatin inhibition—most notably the blockade of activin signaling.
Beyond myostatin inhibition, rodent studies examining muscular dystrophy and acute tissue injury models have documented reduced collagen deposition and decreased fibrotic tissue formation following vector-mediated Follistatin administration. By binding free activin A—a known mediator of tissue inflammation and fibroblast proliferation—Follistatin helps suppress the cascade leading to extracellular matrix remodeling and scarring in experimental models.
In vitro studies using murine C2C12 myoblasts further demonstrate that exposure to recombinant Follistatin stimulates myotube fusion and increases myogenin expression. These cell-culture models provide a controlled environment to quantify down-stream signaling events, including the phosphorylation of Akt and p70S6K, independent of systemic hormonal variations.
Because recombinant proteins like Follistatin possess complex secondary structures and higher molecular weights than short linear peptides, verifying structural integrity and batch purity is non-negotiable for reproducible scientific inquiry. Laboratories procuring research compounds online must insist on lot-specific documentation verified by independent, accredited testing facilities.
PX1 Research enforces a strict quality control matrix. Every lot of recombinant protein undergoes high-performance liquid chromatography (RP-HPLC) to verify chemical purity standards exceeding 98%. Additionally, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or electrospray ionization liquid chromatography-mass spectrometry (ESI-LC-MS) is performed to confirm precise molecular weight and primary sequence identity.
Researchers can inspect authentic Certificates of Analysis (COA) directly through the PX1 Research Library. These reports detail liquid chromatograms, mass spectrum plots, and lot numbers, ensuring that laboratory reagents delivered to your research institution perform consistently across longitudinal trials.
In recombinant protein expression systems—typically bacterial (E. coli) or mammalian cell lines—bacterial endotoxins (lipopolysaccharides / LPS) pose a major threat to experimental validity. Exposure of cell cultures or animal tissues to elevated endotoxin levels triggers unwanted Toll-like receptor 4 (TLR4) inflammatory cascades, confounding gene expression profiling and metabolic assays.
To protect in vitro assays and preclinical animal models from inflammatory interference, PX1 Research measures residual endotoxins using Chromogenic Reagent Limulus Amebocyte Lysate (LAL) testing protocols. Our research-grade protein formulations maintain strict endotoxin thresholds (typically <1.0 EU/μg protein), ensuring that observed cellular responses are driven entirely by protein-receptor interactions rather than immune activation.
Principal investigators purchasing reagents for cell culture work or rodent models can request lot-specific endotoxin validation metrics when setting up a dedicated wholesale laboratory account.
When designing protocols to investigate target pathways in cellular proliferation, hypertrophy, or tissue repair, researchers frequently compare Follistatin to other prominent peptides within similar research domains. Key comparable research compounds include IGF-1 LR3, BPC-157, and Mechano Growth Factor (MGF).
While IGF-1 LR3 functions primarily as a potent agonist at the Receptor Tyrosine Kinase (RTK) IGF-1 receptor—directly stimulating downstream MAPK/ERK and PI3K/Akt signaling cascades—Follistatin acts via ligand sequestration, neutralizing inhibitory proteins (myostatin/activin) rather than activating receptors directly. Conversely, tissue repair peptides like BPC-157 modulate VEGFR2 pathways and nitric oxide synthases to promote focal angiogenesis. Furthermore, splice variants such as Mechano Growth Factor (MGF) act locally in response to mechanical overload to activate satellite cells. Understanding these distinct mechanistical frameworks allows researchers to select appropriate single agents or synergistic comparative cohorts for multi-arm laboratory protocols.
Recombinant Follistatin is supplied as a sterile, lyophilized (freeze-dried) powder to maximize long-term molecular stability during transport and storage. Proper handling and reconstitution protocols must be observed to avoid protein denaturation, aggregation, or loss of biological activity.
Prior to reconstitution, vials should be brought to room temperature inside a laminar flow hood to prevent condensation on the inner walls. Reconstitution should be performed using sterile, deionized laboratory-grade water or sterile phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of downstream assays. If micro-volume dispenses or extended multi-dose sampling from a single container is required, bacteriostatic water containing 0.9% benzyl alcohol may be utilized.
To dissolve the lyophilized cake, inject the diluent along the glass wall of the vial rather than directing the liquid jet straight onto the protein pellet. Gently swirl or roll the vial between your palms until complete dissolution is achieved. Violent vortexing or agitation must be avoided, as high shear forces can cause mechanical denaturation and irreversible aggregation of complex secondary structures.
Lyophilized proteins demonstrate higher resistance to thermal degradation than aqueous solutions. Unreconstituted lyophilized Follistatin vials can be stored at -20°C to -80°C for long-term preservation (up to 24 months). For short-term transit, room temperature stability is maintained without loss of integrity, supported by PX1 Research's expedited shipping protocols.
Once reconstituted into aqueous solution, the protein becomes significantly more vulnerable to thermal degradation and proteolysis. Reconstituted stock solutions should be aliquoted into single-use microcentrifuge tubes using low-protein-binding polypropylene vessels to prevent repeated freeze-thaw cycles, which rupture tertiary protein conformations. Liquid aliquots stored at 2°C to 8°C should be utilized within 7 to 14 days, while aliquots frozen at -80°C remain stable for up to 6 months.
PX1 Research streamlines procurement for university departments, private research organizations, and industrial laboratories worldwide. Recognizing that experimental timelines require punctual logistics, PX1 maintains dual distribution facilities in California and Arizona, offering same-day dispatch for orders placed Monday through Friday prior to cutoff times.
Whether ordering single reference standards or bulk quantities for high-throughput screening, scientific institutions receive fully traceable shipments accompanied by detailed safety data sheets (SDS) and lot verification documentation. Researchers interested in standing supply contracts or bulk institutional pricing are encouraged to establish a wholesale laboratory account with our technical logistics team.
What is the primary difference between Follistatin-315 and Follistatin-288?
Follistatin-315 is the predominant circulating systemic isoform with a C-terminal region that masks its heparin-binding site until cleaved, allowing it to diffuse broadly. Follistatin-288 possesses an unmasked, highly basic C-terminal domain that binds strongly to cell-surface heparan sulfate proteoglycans, confining its activity primarily to local membrane compartments.
Is Follistatin supplied by PX1 Research intended for human consumption?
No. All products supplied by PX1 Research, including recombinant Follistatin, are strictly formulated and distributed for laboratory research, in vitro assays, and preclinical animal models. They are never for human, clinical, veterinary, or therapeutic use.
How is the purity of Follistatin verified?
Purity is established using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm sample homogeneity (>98%), combined with Mass Spectrometry (LC-MS or MALDI-TOF) to verify exact molecular weight and amino acid sequence identity.
Why is endotoxin testing critical for recombinant Follistatin?
Bacterial endotoxins (lipopolysaccharides) can bind TLR4 receptors on target cell lines or host tissues in preclinical models, triggering non-specific inflammatory signaling pathways that invalidate downstream transcription and protein expression data.
What diluent should be used for reconstituting lyophilized Follistatin?
Reconstitution is typically performed using sterile laboratory-grade water or sterile phosphate-buffered saline (PBS, pH 7.4). For multi-use laboratory vials requiring preservation over several days at 4°C, sterile bacteriostatic water containing 0.9% benzyl alcohol may be used.
How should reconstituted Follistatin be stored to prevent degradation?
Reconstituted liquid stock solutions should be divided into single-use aliquots using low-binding polypropylene tubes and stored at -80°C to prevent degradation from freeze-thaw cycles. Short-term liquid storage at 2°C to 8°C should not exceed 7 to 14 days.
Where are PX1 Research peptides manufactured and dispatched from?
PX1 Research peptides are manufactured in CGMP-compliant facilities within the United States. Orders are dispatched directly from primary distribution hubs in California and Arizona with same-day shipping available Monday through Friday.
How does Follistatin compare to IGF-1 LR3 in laboratory research?
Follistatin works primarily by sequestering negative regulators like myostatin and activin A to block ActRIIB receptor binding. In contrast, IGF-1 LR3 acts directly as a receptor agonist on the IGF-1 Receptor Tyrosine Kinase pathway to stimulate intracellular kinase signaling cascades.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.